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AbstrAct
Introduction Cardiovascular diseases are the leading 
cause of morbidity and mortality among individuals 
with diabetes. Despite the beneficial effects of 
antidiabetic drugs (ADDs) in terms of lowering 
haemoglobin A1c, several ADDs have been shown to 
increase the risk of cardiovascular events. Given the 
high prevalence of cardiovascular disease among 
individuals with diabetes, it is important to weigh 
the benefits of ADDs against their cardiovascular 
safety. Therefore, the objective of the current study 
is to conduct a systematic review with network 
meta-analysis to compare the effects of different oral 
pharmacological classes of ADDs on cardiovascular 
safety.
Methods and analysis Randomised clinical trials 
(RCTs) and observational studies published in 
English up to 31 January 2017, and which include 
direct and/or indirect evidence, will be included. 
Studies will be retrieved by searching four electronic 
databases and cross-referencing. Dual selection 
and abstraction of data will occur. The primary 
outcome will be cardiovascular mortality. Secondary 
outcomes will include all-cause mortality, new event 
of acute myocardial infarction, stroke (haemorrhagic 
and ischaemic), hospitalisation for acute coronary 
syndrome and urgent revascularisation procedures. 
Risk of bias will be assessed using the Cochrane 
Risk of Bias assessment instrument for RCTs and the 
Strengthening the Reporting of Observational Studies 
in Epidemiology instrument for observational studies. 
Network meta-analysis will be performed using 
multivariate random-effects meta-regression models. 
The surface under the cumulative ranking curve will 
be used to provide a hierarchy of ADDs that increase 
cardiovascular mortality.
Dissemination The results of this study will be presented 
at a professional conference and submitted to a peer-
reviewed journal.
PrOsPErO registration number CRD42017051220.
IntrODuctIOn
rationale
Diabetes is a global public health problem, 
with prevalence expected to increase from 
382 million to 592 million people by 2035.1 
It is the seventh leading cause of death in 
the USA, with cardiovascular (CV) disease 
being the most common cause of death 
from diabetes.2 Importantly, type 2 diabetes 
mellitus (T2DM) more than doubles the risk 
of CV events.3 4 Annual per-person medical 
care cost of treating adults with T2DM and 
CV disease is US$10 172, approximately 
two times greater than the cost of treating 
T2DM alone.5 
Pharmacotherapy is the mainstream 
strategy to manage diabetes by controlling 
haemoglobin A1c (HbA1c), which is 
important to reduce the risk of CV events 
and premature mortality.6 7 However, in 2007, 
the safety of rosiglitazone, a member of the 
thiazolidinedione class of antidiabetic drugs 
(ADDs), was questioned.8 Specifically, rosigl-
itazone was found to be associated with an 
increased risk of heart attacks, stroke and 
mortality from CV events.8 In addition to 
rosiglitazone, the CV safety of several other 
ADDs, including pioglitazone and sulfony-
lureas, has been questioned.9–15 For example, 
while dipeptidyl peptidase-4 inhibitors 
(DPP-4Is) were shown to be associated with 
decreased hospitalisation due to heart failure 
in one study,16 another study reported a 
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Protocol
strengths and limitations of this study
 ► To the best of our knowledge, this is the first 
systematic review with network meta-analysis that 
compares the cardiovascular safety of different 
classes of antidiabetic  drugs based on data 
from both randomised clinical trials (RCTs) and 
observational studies.
 ► Common to most meta-analyses, significant and 
unexplained heterogeneity may exist.
 ► Like any aggregate data meta-analysis, the risk for 
ecological fallacy exists.
 ► Few RCTs may report data on cardiovascular 
mortality.
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higher rate of hospitalisation due to heart failure among 
those using DPP-4Is.17 Based on the potential deleterious 
consequences of ADDs and subsequent CV events, the US 
Food and Drug Administration (FDA) revised their policy 
in 2008 to place greater emphasis on examining CV safety 
for all trials testing newer ADDs.18 However, the effects 
of ADDs on CV events, including CV mortality, have not 
been firmly established.8 10 To the best of the authors’ 
knowledge, only one previous network meta-analysis has 
been conducted with respect to the CV safety of ADDs.19 
In this study, authors included randomised clinical trials 
(RCTs) that were 24 weeks or longer. No statistically 
significant difference was reported between CV mortality 
and any drug class. While these findings are encouraging, 
the inclusion of only RCTs may be potentially limiting, 
given that prior to 2008, ADDs were only required to 
prove clinical efficacy in terms of lowering HbA1c. As a 
result, the clinical trials of the drugs that received regu-
latory approval before 2008 may not have reported CV 
outcomes. Consequently, a need exists for a meta-analysis 
that includes both RCTs and observational studies so that 
adverse outcomes can be appropriately documented. In 
addition, it has recently been suggested that RCTs and 
observational studies should not be considered in isola-
tion.20 Furthermore, additional studies may have been 
published since the previous studies search for eligible 
trials (21 March 2016).19 Given the former, a need exists 
for an updated network meta-analysis that also includes 
observational studies.
Objective
The primary objective of this study is to conduct a system-
atic review with network meta-analysis of randomised 
trials and observational studies to compare the effects 
of different pharmacological classes of ADDs on CV 
mortality. The network meta-analytic approach is 
appropriate here because it allows for the inclusion 
of multiple interventions from both direct and indi-




This study will follow the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses guidelines22 for 
meta-analyses of healthcare interventions and the current 
protocol report follows the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses Protocols.23 
This protocol is registered in International Prospective 
Register of Systematic Reviews (trial registration number: 
CRD42017051220).
Eligibility criteria
Studies that meet the following criteria will be included: 
(1) randomised trials and observational studies; (2) 
adults ≥18 years of age with T2DM, either with or 
without a history of CV disease; (3) at least one oral 
ADD intervention group; (4) comparative control 
group for randomised trials that do not include more 
than one oral ADD; (5) data on CV mortality and/
or major adverse cardiac events; (6) studies published in 
English up to 31 January 2017. The decision to include 
patients with T2DM with or without a history of CV 
disease was made based on our preliminary search of 
clinical trials that included patients with either a history 
of CV disease or those who are at a heightened risk for 
CV disease. Because T2DM and a history of CV disease 
are both associated with an increased risk of acute 
myocardial infarction (AMI) and stroke,24 we decided 
to include patients with T2DM with or without a history 
of CV disease and compare new events of AMI and 
stroke between the two groups. Such criteria will also 
allow for selected comparisons. A decision was made to 
only include oral ADDs because there are two classes 
of injectable antidiabetic medications approved for 
treatment in the USA. These include insulin  and gluca-
gon-like peptide-1 receptor agonists. Typically, insulin 
and other injectable drugs are not first-line therapies in 
the treatment of T2DM. These are prescribed to more 
severe patients who are not able to achieve appropriate 
glucose levels with other therapies. Therefore, to keep 
the study population more uniform, only oral antidia-
betic agents will be included.
Direct comparisons will be made from the studies 
comparing two or more ADDs and indirect compar-
isons will be made from studies comparing an ADD to 
a placebo. Both randomised clinical trials and observa-
tional studies will be included because randomised clin-
ical trials were not required to include CV outcomes 
before 2008, and it has recently been suggested that RCTs 
and observational studies should not be looked at in isola-
tion.20 Major adverse cardiac events will be defined as an 
incidence of AMI, stroke, hospitalisation for acute coro-
nary syndrome and urgent revascularisation procedures. 
These measures were identified by the US FDA to ascer-
tain the CV safety of ADDs in the regulatory guidelines 
issued for the industry.18
Information sources
The following databases will be searched from their 
inception forward for potentially eligible studies in 
English language published on or before 31 January 
2017: (1) PubMed, (2) Scopus, (3) Web of Science, (4) 
Cochrane Central Register of Controlled Clinical Trials, 
(5) clinical trials registry ( ClinicalTrials. gov). In addition, 
cross-referencing from retrieved studies will be conducted.
search strategy
Search strategies adapted from a previous research19 will 
be developed using text words and Medical Subject Head-
ings. Electronic databases will be searched for studies 
on the effects of oral ADDs on CV safety in adults with 
T2DM. The first author will conduct all database searches. 
A preliminary search strategy for PubMed is shown in 
online supplementary file 1. The search strategy for all 
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Figure 1 Flow diagram of study selection process.
other databases will be adapted based on the require-
ments of each database.
study records
Study selection
All studies extracted from electronic databases using the 
search strategy will be imported into EndNote V.X7.5. 
Duplicate studies will be removed electronically using 
the ‘Find Duplicates’ tool in EndNote. The studies will 
be examined again manually to find and delete any addi-
tional duplicates. The first two authors will select studies 
independent of each other. Complete articles will be 
obtained for all titles and abstracts that appear to meet 
the inclusion criteria or where there is any uncertainty. 
Reasons for exclusion will be coded as one or more of 
the following: (1) inappropriate population, (2) inap-
propriate intervention, (3) inappropriate comparison, 
(4) inappropriate outcome(s), (5) inappropriate study 
design and (6) other. After selection, the first two authors 
will review their selections and resolve any discrepancies 
by consensus. If consensus cannot be reached, the third 
author will be consulted. The overall agreement rate 
prior to correcting discrepant items will be calculated 
using Cohen’s kappa (κ) statistics. Once discrepancies are 
resolved, the overall precision of searches will be calcu-
lated by dividing the number of studies included by the 
total number of studies screened after removing dupli-
cates. The number needed to read will then be calculated 
as the inverse of the precision. A flow diagram that depicts 
the search process and an online supplementary file that 
includes a reference list of all studies excluded (including 
the reason(s) for exclusion) will be included in the study. 
The proposed structure for the flow diagram is shown in 
figure 1.
Data abstraction
Before initiating data abstraction, a codebook will be 
developed in Microsoft Excel 2013. The codebook will be 
developed by the first author with input from the third 
author. The major categories of variables to be coded will 
include: (1) study characteristics (author, journal, year, 
etc); (2) participant characteristics (age, sex, HbA1c, CV 
disease at baseline, etc); (3) intervention characteristics 
(pharmacological class of ADDs, dose, route of admin-
istration, etc); (4) control characteristics; (5) outcome 
data for CV mortality, all-cause mortality, incidence of 
AMI, stroke, hospitalisation for acute coronary syndrome 
and urgent revascularisation procedures. The first two 
authors will abstract data from selected studies, inde-
pendent of each other, using the codebook in Micro-
soft Excel. On completion, both authors will review 
the codebooks and resolve discrepancies by consensus. 
If consensus cannot be reached, the third author will 
provide a recommendation. Prior to correcting disagree-
ments, the overall agreement rate will be calculated using 
Cohen’s κ statistic.
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Outcomes and prioritisation
The primary study outcome will be CV mortality. 
Secondary outcomes will include all-cause mortality, new 
event of AMI, stroke, hospitalisation for acute coronary 
syndrome and urgent revascularisation procedures.
risk of bias assessment in individual studies
Risk of bias for RCTs will be assessed using the Cochrane 
Risk of Bias instrument.25 Observational studies will be 
assessed using the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) instru-
ment.26 Bias in RCTs will be evaluated for six domains: 
(1) random sequence generation, (2) allocation conceal-
ment, (3) blinding of participants and personnel, (4) 
blinding of outcome assessors, (5) incomplete outcome 
data and (6) selective reporting. Each study will be clas-
sified as having a high, low or unclear risk of bias overall 
and for each domain. The overall risk of bias will be clas-
sified as high if any one of the domains is considered 
high risk. The STROBE instrument is a checklist of 22 
items that evaluates the quality of reporting for obser-
vational studies. No study will be excluded based on the 
results of risk of bias assessment.26 The first two authors 
will conduct all risk of bias assessments independent of 
each other. The two authors will then review the results 
for risk of bias assessment and resolve any discrepancies 
by consensus. If consensus cannot be reached, the third 
author will be consulted.
Data synthesis
Calculation of effect sizes
All analyses will be conducted using the natural log of 
OR and then transformed back to ORs for presentation 
purposes. If OR is not reported, it will be calculated 
from data reported in the study. If data are not avail-
able to calculate OR, it will be requested from the study 
authors. Secondary outcomes will be calculated using 
the same procedure as for our primary outcome. If a 
study includes both direct and indirect comparisons, 
only direct comparison data will be included given that 
the primary focus of the current study is to compare the 
CV safety between different ADDs. The data augmenta-
tion approach will be used to make direct comparisons if 
the control group is placebo.27 In this technique, direct 
evidence studies that lack a control (placebo) group 
will have one generated from the weighted average of 
the arm-specific means and SD.28
Pooled estimates for change in outcomes
Network maps will be drawn to depict the treatments 
that are directly compared against each other and the 
amount of evidence available for each treatment and its 
comparator. Separate network maps will be presented for 
each outcome. Contribution plots for each outcome will 
be generated to determine the most dominant compari-
sons for each network estimate, as well as for the entire 
network. The weights applied will be a function of the 
variance of the direct treatment effect and the network 
structure, the product being a per cent contribution 
of each direct comparison to each network estimate. 
Network and contribution plots will be produced using 
the networkplot and netweight commands, respectively,29 in 
Stata/IC for Mac V.14.0 (STATA; 2016).
Prior to conducting network meta-analysis, pair-
wise meta-analysis using random-effects models will be 
conducted in order to examine statistical heterogeneity 
within each comparison.21 Heterogeneity will be assessed 
using Cochran’s Q statistics and I2, an extension of Q.30 31 
A Q statistic <0.10 and/or an I2 value >50% will be consid-
ered to represent significant heterogeneity. On comple-
tion of pairwise meta-analysis, network meta-analysis will 
be performed using multivariate random-effects models 
based on the mvmeta command in Stata/IC for Mac 
V.14.0.32 Non-overlapping 95% CIs will be considered 
to represent statistically significant changes. Separate 
network meta-analysis models will be used to compare CV 
mortality, all-cause mortality, incidence of AMI, stroke, 
hospitalisation for acute coronary syndrome and urgent 
revascularisation procedures.
Sub-group analyses will be conducted to examine the 
association between our primary outcome and oral ADDs. 
These will include year of drug approval by the US FDA, 
presence or absence of CV disease risk at baseline, HbA1c 
at the baseline, number of comorbidities, type of treat-
ment (monotherapy, dual therapy or triple therapy) 
and the country the study was conducted in. Secondary 
outcomes will be handled using the same approach.
We will examine the consistency of the estimates of 
treatment effects from direct and indirect evidence for 
each outcome using the mvmeta command in Stata.28 An 
alpha value <0.05 will be considered to represent statis-
tically significant inconsistency. Prediction intervals 
will be used to enhance the interpretation of findings 
and provide an estimate of expected results in a future 
study.28 32 Prediction intervals will be generated using 
the mvmeta and interval plot29 commands in Stata/IC 
for Mac V.14.0.
Meta-biases
Small-study effects (publication bias, etc) will be assessed 
using comparison-adjusted funnel plots. Unlike tradi-
tional funnel plots in pairwise meta-analysis, funnel plots 
in network meta-analysis need to account for the fact that 
studies estimate treatment effects for different compari-
sons. Consequently, there is no single reference line from 
which symmetry can be evaluated. For the comparison-ad-
justed funnel plot, the horizontal axis will represent the 
difference between study-specific effect sizes from the 
comparison-specific summary effect. In the absence of 
small-study effects, the comparison-adjusted funnel plot 
should be symmetric around the zero line. Since the 
treatments need to be organised in some meaningful way 
to examine how small studies may differ from large ones, 
comparisons will be defined so that all refer to an active 
treatment versus a control group. Comparison-adjusted 
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Table 1 Covariates that will be included in the study
Characteristics Variables
Study Publication year, country the study was conducted in, type of study (RCT, cohort, case–control, etc), 
duration of the study, follow-up duration.
Participant Age, sex, HbA1c, risk of cardiovascular disease, presence or absence of cardiovascular disease, medication 
status, baseline condition of participants (eg, disease severity).
Intervention Name of the drug, pharmacological class, dose, route of administration.
Comparator Name of the drug, pharmacological class, dose, route of administration.
Outcome Cardiovascular mortality, all-cause mortality, incidence of AMI, stroke, hospitalisation for acute coronary 
syndrome and urgent revascularisation procedures.
AMI, acute myocardial infarction; HbA1c, haemoglobin A1c; RCT, randomised clinical trial.
funnel plots will be generated using the netfunnel 
command29 in Stata/IC for Mac V.14.0.
Transitivity (similarity in the distribution of potential 
effect modifiers across the different pairwise compar-
isons)33 will be evaluated using random-effects network 
meta-regression while controlling for the different study 
designs within each comparison. Potential effect modi-
fiers will include age, gender, baseline HbA1c, duration 
of T2DM, obesity, presence of CV disease at baseline and 
medication status. In addition, because individuals taking 
medication are more likely to have severe disease or more 
comorbidity than those without medication, we will also 
include baseline condition of the patient (eg, disease 
severity) in our regression models. However, since this is an 
aggregate data meta-analysis and if the patients included 
within each study are heterogeneous (eg, different levels 
of disease severity within the same study), we will include 
as a covariate those studies that control for such factors 
versus those that do not. Table 1 provides a complete list 
of covariates that we plan to include. Transitivity analysis 
will be conducted using the mvmeta command28 in Stata/
IC for Mac V.14.0.
Ranking analysis is a major advantage of network 
meta-analysis because it allows one to rank all interven-
tions for the outcome of interest. For the current study, 
we will generate ranking plots for a single outcome using 
probabilities.34 35 However, since ranking treatments 
based solely on the probability of each treatment being 
the best does not account for the uncertainty in the rela-
tive treatment effects and the potential for assigning 
higher ranks in which little information is available, 
rankograms and cumulative ranking probability plots will 
be used to show ranking probabilities along with their 
uncertainty for changes in our primary and secondary 
outcomes.34 35 Surface under the cumulative ranking 
curves (SUCRA), a transformation of mean ranks, 
will be used to provide a hierarchy of treatments while 
accounting for the location and variance of all treatment 
effects.34 35 Larger SUCRA values are indicative of better 
ranks for the treatment. Separate ranking analyses will be 
conducted for all primary and secondary outcomes using 
the mvmeta28 and SUCRA29 commands in Stata/IC for 
Mac V.14.0.
software used for data synthesis
All data will be analysed using Stata/IC for Mac V.14.0.
confidence in the cumulative evidence
Strength in the body of evidence will be assessed using 
the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) instrument for 
network meta-analysis.36 Two main outputs are reported 
in a network meta-analysis: pairwise effect estimates and 
treatment rankings. Since the two outputs are gener-
ated using different techniques, they may differ between 
each other. Therefore, it is important to assess the level 
of confidence to be placed on each output. The level 
of confidence will be assessed using GRADE across four 
domains: (1) study limitations, (2) joint consideration 
of indirectness and transitivity, (3) joint consideration 
of statistical heterogeneity and statistical inconsistency, 
(4) imprecision and publication bias. Based on these 
assessments, the overall strength of evidence will be 
ranked as either high, moderate, low or very low. The 
overall confidence will be classified as high if any one of 
the domains is considered high.
rEgIstrAtIOn
In accordance with Primary Reporting Items for 
Systematics Reviews and Meta-Analyses Protocols (PRIS-
MA-P,) our systematic review with network meta-analysis 
was registered with the International Prospective Register 
of Systematic Reviews (PROSPERO) on 15 April 15, 2017 
(registration number: CRD42017051220).
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